Dublin, OH (Aril 8, 2015) – Eli Lilly has recognized Dublin, Ohio-based Biosortia Pharmaceuticals with the 2014 Open Innovation Drug Discovery (OIDD) Collaborator of the Year award.

The Collaborator of the Year award is the result of the innovative results and progress created by Biosortia and Lilly’s OIDD team.

Biosortia, a leader in discovering and co-develop novel and potent bioactive compounds, is primarily focused on drug discovery for cancer, infectious disease, and anti-inflammatory therapeutics. Since entering Lilly’s OIDD program in 2012, Biosortia has nearly 100% acceptance of the compounds it has submitted, far exceeding the 40% to 50% average of all other providers combined.

“Lilly’s OIDD program and the innovation that their team develops has created an opportunity for Biosortia to provide Lilly with the type of chemistry they are seeking… new, highly potent chemistry, resulting in new mechanisms of action,” says Dr. Guy Carter, Biosortia’s Chief Science Officer. Carter, formerly head of Natural Products Discovery at Wyeth Pharmaceuticals, leads Biosortia’s internationally renowned collaborative scientific team that aquatic microbial consortia containing vast chemistry diversity that elicits a wide range of biological effects. Biosortia accesses this new chemistry from previously inaccessible aquatic ecosystems.

“Lilly’s recognition of our collaborative relationship further validates the importance of our distinct capability to provide our customers an important recurring pipeline of novel chemistry they are seeking and to assist in the co-development of these important optimized leads for their drug discovery pipeline. The highly innovative team of professionals within Lilly’s OIDD program has led to an important collaboration relationship,” says Biosortia President and CEO, Kurt Dieck.

To date, Biosortia has research agreements with 4 top big pharma companies with more in the pipeline and is planning to release its next fraction library to Lilly and others in late April 2015.

###

About Biosortia Pharmaceuticals – Biosortia has a proven and unique ability to obtain unculturable aquatic microbial consortia from the natural environment in unprecedented quantities allowing its research team to discover a diverse array of new natural products. Biosortia is actively engaging pharmaceutical research and development organizations to explore the huge opportunity of exploring aquatic microbial consortia for potential therapeutic agents.

About JLABS – The Biosortia Pharmaceutical operations are located at JLABS in San Diego (JLABS @SD). JLABS is a 40,000 square-foot life science innovation center, located in San Diego. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, JJI does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own or by initiating a separate external partnership with JJI or any other company.

If you’d like more information about the announcement or Biosortia, please contact Chad Hummell of Biosortia at 614-203- 8040 or ch******@*******ia.com.